Show simple item record

dc.contributor.authorHatch, SB
dc.contributor.authorYapp, C
dc.contributor.authorMontenegro, RC
dc.contributor.authorSavitsky, P
dc.contributor.authorGamble, V
dc.contributor.authorTumber, A
dc.contributor.authorRuda, GF
dc.contributor.authorBavetsias, V
dc.contributor.authorFedorov, O
dc.contributor.authorAtrash, B
dc.contributor.authorRaynaud, F
dc.contributor.authorLanigan, R
dc.contributor.authorCarmichael, L
dc.contributor.authorTomlin, K
dc.contributor.authorBurke, R
dc.contributor.authorWestaway, SM
dc.contributor.authorBrown, JA
dc.contributor.authorPrinjha, RK
dc.contributor.authorMartinez, ED
dc.contributor.authorOppermann, U
dc.contributor.authorSchofield, CJ
dc.contributor.authorBountra, C
dc.contributor.authorKawamura, A
dc.contributor.authorBlagg, J
dc.contributor.authorBrennan, PE
dc.contributor.authorRossanese, O
dc.contributor.authorMüller, S
dc.date.accessioned2017-03-24T13:58:37Z
dc.date.issued2017-01
dc.identifier.citationEpigenetics & chromatin, 2017, 10 pp. 9 - ?
dc.identifier.issn1756-8935
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/490
dc.identifier.eissn1756-8935
dc.identifier.doi10.1186/s13072-017-0116-6
dc.description.abstractBackground Histone lysine demethylases (KDMs) are of interest as drug targets due to their regulatory roles in chromatin organization and their tight associations with diseases including cancer and mental disorders. The first KDM inhibitors for KDM1 have entered clinical trials, and efforts are ongoing to develop potent, selective and cell-active 'probe' molecules for this target class. Robust cellular assays to assess the specific engagement of KDM inhibitors in cells as well as their cellular selectivity are a prerequisite for the development of high-quality inhibitors. Here we describe the use of a high-content cellular immunofluorescence assay as a method for demonstrating target engagement in cells.Results A panel of assays for the Jumonji C subfamily of KDMs was developed to encompass all major branches of the JmjC phylogenetic tree. These assays compare compound activity against wild-type KDM proteins to a catalytically inactive version of the KDM, in which residues involved in the active-site iron coordination are mutated to inactivate the enzyme activity. These mutants are critical for assessing the specific effect of KDM inhibitors and for revealing indirect effects on histone methylation status. The reported assays make use of ectopically expressed demethylases, and we demonstrate their use to profile several recently identified classes of KDM inhibitors and their structurally matched inactive controls. The generated data correlate well with assay results assessing endogenous KDM inhibition and confirm the selectivity observed in biochemical assays with isolated enzymes. We find that both cellular permeability and competition with 2-oxoglutarate affect the translation of biochemical activity to cellular inhibition.Conclusions High-content-based immunofluorescence assays have been established for eight KDM members of the 2-oxoglutarate-dependent oxygenases covering all major branches of the JmjC-KDM phylogenetic tree. The usage of both full-length, wild-type and catalytically inactive mutant ectopically expressed protein, as well as structure-matched inactive control compounds, allowed for detection of nonspecific effects causing changes in histone methylation as a result of compound toxicity. The developed assays offer a histone lysine demethylase family-wide tool for assessing KDM inhibitors for cell activity and on-target efficacy. In addition, the presented data may inform further studies to assess the cell-based activity of histone lysine methylation inhibitors.
dc.formatElectronic-eCollection
dc.format.extent9 - ?
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHela Cells
dc.subjectHumans
dc.subjectPaclitaxel
dc.subjectHistones
dc.subjectProtein Isoforms
dc.subjectEnzyme Inhibitors
dc.subjectMicroscopy, Fluorescence
dc.subjectInhibitory Concentration 50
dc.subjectPhylogeny
dc.subjectApoptosis
dc.subjectMutagenesis
dc.subjectCatalytic Domain
dc.subjectMethylation
dc.subjectBiocatalysis
dc.subjectProtein Stability
dc.subjectHistone Demethylases
dc.titleAssessing histone demethylase inhibitors in cells: lessons learned.
dc.typeJournal Article
dcterms.dateAccepted2017-02-21
rioxxterms.versionofrecord10.1186/s13072-017-0116-6
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2017-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEpigenetics & chromatin
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Hit Discovery & Structural Design
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 1
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Target Evaluation and Molecular Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Structural Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Structural Biology/Hit Discovery & Structural Design
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/19/20 Starting Cohort
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Hit Discovery & Structural Design
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 1
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Target Evaluation and Molecular Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Structural Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Structural Biology/Hit Discovery & Structural Design
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/19/20 Starting Cohort
pubs.publication-statusPublished
pubs.volume10
pubs.embargo.termsNot known
icr.researchteamClinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)en_US
icr.researchteamMedicinal Chemistry 1en_US
icr.researchteamTarget Evaluation and Molecular Therapeuticsen_US
icr.researchteamHit Discovery & Structural Designen_US
dc.contributor.icrauthorRossanese, Oliviaen
dc.contributor.icrauthorBurke, Rosemaryen
dc.contributor.icrauthorRaynaud, Florenceen
dc.contributor.icrauthorBavetsias, Vassiliosen
dc.contributor.icrauthorBlagg, Julianen
dc.contributor.icrauthorCarmichael, LeAnneen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0